Literature DB >> 28831709

Predictive Validation and the Re-Analysis of Cost-Effectiveness: Do We Dare to Tread?

Jonathan Karnon1, Hossein Hajiali Afzali2.   

Abstract

Mesh：

Year:  2017        PMID： 28831709     DOI： 10.1007/s40273-017-0561-x

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  3 in total

1.  Uncertainty and validation of health economic decision models.

Authors:  Lois G Kim; Simon G Thompson
Journal:  Health Econ       Date:  2010-01       Impact factor: 3.046

Review 2.  Model performance evaluation (validation and calibration) in model-based studies of therapeutic interventions for cardiovascular diseases : a review and suggested reporting framework.

Authors:  Hossein Haji Ali Afzali; Jodi Gray; Jonathan Karnon
Journal:  Appl Health Econ Health Policy       Date:  2013-04       Impact factor: 2.561

3.  What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia.

Authors:  Jonathan Karnon; Ainul Shakirah Shafie; Nneka Orji; Sofoora Kawsar Usman
Journal:  Cost Eff Resour Alloc       Date:  2016-10-13
  3 in total
  1 in total

1.  Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies.

Authors:  Amr Makady; Ard van Veelen; Páll Jonsson; Owen Moseley; Anne D'Andon; Anthonius de Boer; Hans Hillege; Olaf Klungel; Wim Goettsch
Journal:  Pharmacoeconomics       Date:  2018-03       Impact factor: 4.981
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.